Not finding it? Sign in to also search OpenAlex live.
-
S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
Andreas Hochhaus, Andreas Burchert, Susanne Saußele, Gabriela Maria Baerlocher, Jiřı́ Mayer, Tim H. Brümmendorf, +20 more
6citations -
Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial
Andreas Hochhaus, Andreas Burchert, Susanne Saußele, Gabriela Maria Baerlocher, Jiřı́ Mayer, Tim H. Brümmendorf, +21 more
21citations -
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
Jonathan L. Kaufman, Jacob P. Laubach, Douglas Weston Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, +21 more
24citations -
Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT
Nico Gagelmann, Dirk‐Jan Eikema, Linda Köster, Tanja Netelenbos, Andrew Bruce McDonald, Anne‐Marie Stoppa, +19 more
0citations -
A17 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY2021 Journal of the Canadian Association of Gastroenterology article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Laurent Peyrin‐Biroulet, Edward V. Loftus, Silvio Danese, Severine A.R.A. Vermeire, William J. Sandborn, Sandeep Nijhawan, +14 more
12citations -
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study2020 The Lancet Haematology article Medicine Multiple Myeloma Research and Treatments Open access cited by 2 patents
Michèle Cavo, Francesca Gay, Meral Beksaç, Lucia Pantani, Maria Teresa Petrucci, Meletios Athanasios Dimopoulos, +54 more
384citations -
Exploring Patient’s Perspectives and Experiences After Start with Inhalation Maintenance Therapy: A Qualitative Theory-Based Study2020 Patient Preference and Adherence article Pharmacology, Toxicology and Pharmaceutics Pharmacy and Medical Practices Open access
Esther Kuipers, Michel Wensing, Peter A. G. M. De Smet, Martina Teichert
4citations -
Maintenance therapy with subcutaneous immunoglobulin in a patient with immune‐mediated neuropathic postural tachycardia syndrome2021 Journal of Translational Autoimmunity article Medicine Cardiovascular Syncope and Autonomic Disorders Open access
Kalliopi Pitarokoili, Andrea Maier, Elena de Moya Rubio, Katrin Hahn, Gerd Wallukat, Diamantis Athanasopoulos, +4 more
11citations -
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial2022 Intestinal Research article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Toshifumi Hibi∥, Satoshi Motoya, Tadakazu Hisamatsu, Fumihito Hirai, Kenji Watanabe, Katsuyoshi Matsuoka, +10 more
15citations -
Real-World Risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia and Other Second Primary Malignancies in Patients with Epithelial Ovarian Cancer Treated with Niraparib Maintenance Therapy: Results from a Postauthorization Safety Study
Maurice J. D. L. van der Vorst, Constanza Maximiano Alonso, Tirza Areli Calderón Boyle, Jeanne M. Schilder, Izabela A. Malinowska, Guilan Ye, +8 more
0citations -
1192P Characterization of patients with newly diagnosed advanced ovarian cancer not receiving maintenance therapy: Results of a prospective real-world study (NOGGO ov54, SCOUT-1)
Pauline Wimberger, Elena Ioana Braicu, Klaus Pietzner, J. Goldmann, Karol Kubiak, Cosima V. M. Brucker, +14 more
0citations -
DOP63 Real World Effectiveness, Safety and Pharmacokinetics of Switching Intravenous Vedolizumab Maintenance treatment to Subcutaneous Vedolizumab Therapy for Inflammatory Bowel Disease2022 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Adriaan Volkers, Tessa Straatmijer, Marjolijn Duijvestein, Andressa Gomes Sales, F van Schaik, M Jeroen, +13 more
2citations -
Hyperkalemia and maintenance of renin–angiotensin system inhibitor therapy after initiating SGLT-2 or DPP-4 inhibitors2024 Nephrology Dialysis Transplantation article Medicine Diabetes Treatment and Management Open access
Alessandro Bosi, Yang Xu, Anne‐Laure Faucon, Tao Huang, Marie Evans, Jung‐Im Shin, +2 more
5citations -
Real-World Risk Of MDS/AML And Other Secondary Primary Malignancies In Patients With Epithelial Ovarian Cancer Treated With Niraparib Maintenance Therapy: Final Results From A Regulatory Safety Study2025 International Journal of Gynecological Cancer article Medicine Multiple and Secondary Primary Cancers Open access
Constanza Maximiano Alonso, Maurice Van Der Vorst, Tirza Areli Calderón Boyle, Jeanne M. Schilder, Izabela A. Malinowska, Guilan Ye, +6 more
0citations -
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML
Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Tim Sauer, +29 more
7citations -
Rationale and Design of GnG-Trial: A Randomized Phase-III Study to Compare Two Schedules of Gemtuzumab Ozogamicin as Adjunct to Intensive Induction Therapy and to Compare Double-Blinded Intensive Postremission Therapy with or Without Glasdegib in Older Patients with Newly Diagnosed AML
Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Tim Sauer, +28 more
0citations -
Dutch ALL11 Study: Improved Outcome for Acute Lymphoblastic Leukemia By Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for ETV6::RUNX1, Down Syndrome and Prednisone Poor Responders
Rob Pieters, Hester A. de Groot‐Kruseman, Femke Verwer, Merian van Overveld, Edwin Sonneveld, Marta F. Fiocco, +10 more
2citations -
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance
Jacob P. Laubach, Jonathan L. Kaufman, Douglas Weston Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, +22 more
24citations -
Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7
Lori Ann Leslie, Gerardo Musuraca, Pau Abrisqueta, Joshua Brody, Jacob Haaber Christensen, Alexander Fosså, +8 more
2citations -
Blended Acceptance and Commitment Therapy Versus Face-to-face Cognitive Behavioral Therapy for Older Adults With Anxiety Symptoms in Primary Care: Pragmatic Single-blind Cluster Randomized Trial (Preprint)
Maartje Witlox, Nadia Garnefski, Vivian Kraaij, Margot W. M. de Waal, Filip Smit, Ernst Thomas Bohlmeijer, +1 more
0citations -
Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7.2024 Journal of Clinical Oncology conference-abstract Medicine Lymphoma Diagnosis and Treatment Open access
Leslie A. Lori, Lorenzo Falchi, Joost S.P. Vermaat, Gerardo Musuraca, David Belada, Marcel Nijland, +8 more
9citations